Formulating with palmitoylethanolamide.
PEA is well behaved: neutral in taste, effectively colorless, thermally stable through normal processing and chemically unreactive toward most common excipients. The two things that will catch you out are its hydrophobicity and its low bulk density.
What to expect on the line
Hydrophobic by nature
Log P around 6 and practically insoluble in water. It will float on an aqueous phase and resist wetting unless you give it a surfactant, a lipid carrier or a dispersion system. Plan for this in any liquid format.
Low bulk density when milled
Micronized grade is fluffy and can carry static. Expect a larger capsule shell than the milligram figure suggests, and specify slip and glidant accordingly.
Thermally forgiving
Melting range 95–101 °C. It survives standard gummy depositing, tabletting and soft-chew extrusion, but should not be held far above its melting point.
Organoleptically quiet
Essentially odorless and tasteless at label doses. Any off-note in a finished product is almost always coming from something else in the matrix.
Chemically unreactive
A simple fatty-acid amide with no ionisable groups at physiological pH. No meaningful incompatibility reported with common minerals, vitamins or botanical extracts.
Photostable in practice
Stored dry, closed and below 25 °C, PEA is a stable solid. Standard opaque or amber finished-pack protection is more than sufficient.
Grade selection and practical notes by dosage form
| Format | Suggested grade | Typical payload | Formulation notes |
|---|---|---|---|
| Hard capsules | M or UM | 300–600 mg | Size 0 or 00 depending on grade density. Add a flow aid; micronized PEA alone flows poorly on high-speed encapsulation. |
| Tablets | M | 300–500 mg | Direct compression is workable with a compressible diluent. Watch capping at high PEA load; wet or roller granulation improves robustness above 40% w/w. |
| Softgels | M or UM | 200–400 mg | Suspend in a lipid vehicle. PEA is dispersible in MCT and similar carriers; this format also gives a natural bioavailability narrative. |
| Gummies & jellies | M | 100–300 mg | Add after the cook step, below 90 °C, into a well-agitated slurry. Micronized grade suspends evenly; normal grade tends to sediment in the depositor. |
| Soft chews (pet) | Normal or M | 50–300 mg | Cold-formed chews tolerate normal grade. Micronized improves homogeneity in small chews where the per-piece dose is critical. |
| Stick packs & sachets | Normal or M | 300–1200 mg | Combine with a fast-melt or effervescent base. Effervescence assists wetting and largely removes the dispersion problem. |
| RTD shots & beverages | CWD | 150–400 mg | Needs a dispersion or emulsification system. Do not attempt with unmodified powder — you will get a ring on the neck of the bottle. |
| Oral films & sublinguals | M | 25–100 mg | Payload is limited by film mechanics and content uniformity is a particle-size problem first. Talk to us before committing to this format. |
| Topical creams & balms | M or UM | 0.5–3% w/w | Disperse into the oil phase before emulsification. Gritty texture is the failure mode; finer grades avoid it. |
| Bulk powder | Normal | — | Scoop-dosed products and further-processing customers. The most economical grade per kilogram. |
Guidance only. Payloads reflect commonly marketed dose points rather than a recommendation; permissible doses and claims vary by jurisdiction.
Where PEA is actually selling
Five categories carry the overwhelming majority of global PEA volume. Each has a different evidence base and a different competitive shape.
Nerve comfort & neuropathic support
The deepest clinical base and the highest consumer intent. Sciatica, diabetic neuropathy and post-surgical nerve discomfort dominate search behavior. Typical positioning: 400 mg micronized, twice daily, with a 60-day trial framing.
Read the neuropathy evidenceJoint & mobility
Supported by a three-arm placebo-controlled knee osteoarthritis trial at 300 and 600 mg/day. Formulates naturally alongside collagen peptides, glucosamine, boswellia and curcuminoids in both human and pet lines.
Companion animal
A genuine controlled trial in 50 dogs and 50 cats gives this category evidence that most pet supplements lack. Veterinary practices in several markets already stock PEA. Underserved on the supply side.
The pet category in detailSleep, mood & cognition
A sleep-onset RCT at 350 mg and a crossover cognition trial at 700 mg with a BDNF endpoint. Earlier-stage evidence, but a natural pairing with melatonin, magnesium and L-theanine.
Women's health
Pelvic pain and endometriosis-associated discomfort, generally as PEA with polydatin. The meta-analytic evidence is real but the authors themselves rate the underlying study quality as poor — position carefully.
Headache & migraine
Two recent randomized trials, including a PEA-plus-melatonin combination that reduced monthly migraine days. Almost no consumer-facing content exists yet, which makes this the most open positioning in the category.
PEA rarely travels alone.
The most differentiated finished products in this category are combinations. We supply the components and can co-mill them to a shared particle-size distribution rather than simply blending them.
- PEA + luteolin — the co-ultramicronized pairing used in most European neuroinflammation work, including post-viral olfactory studies.
- PEA + polydatin — the combination studied in endometriosis-associated pelvic pain.
- PEA + melatonin — the basis of a recent randomized migraine-prevention trial.
- PEA + magnesium / B-complex — the commercial mainstream of nerve-comfort formulations.
- PEA + collagen / glucosamine / boswellia — joint and mobility stacks in both human and pet formats.
- PEA + dispersion system — for beverages and any format where cold-water wetting matters.
Send us the dosage form and we will send back a grade recommendation
Tell us the format, the target dose, the run size and the market. You get a grade recommendation, a specification, a representative certificate of analysis and an honest note on anything that will be difficult.